DIGP: AI 评分 44/100 — AI 分析 (4月 2026)

Digipath, Inc. provides cannabis and hemp lab testing services in Nevada, catering to licensed medical marijuana enterprises. The company focuses on ensuring product safety and compliance through comprehensive testing and analysis.

Key Facts: AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Digipath, Inc. offers specialized cannabis and hemp testing services, ensuring safety and regulatory compliance for Nevada's licensed medical marijuana industry. The company distinguishes itself through comprehensive contaminant screening and educational resources, positioning it as a key player in the cannabis quality assurance sector.

DIGP是做什么的？

Digipath, Inc., established in 2010 and headquartered in Las Vegas, Nevada, operates as a cannabis and hemp testing laboratory. The company serves Nevada's licensed medical marijuana enterprises, offering a suite of testing services designed to ensure product safety and regulatory compliance. Digipath's services include screening for contaminants such as residual solvents, pesticides, heavy metals, and microbial contaminants in cannabis, cannabis-infused products, hemp, and other botanical nutraceuticals. These tests cater to growers, dispensaries, caregivers, producers, patients, and end-users, ensuring that products meet stringent quality standards. Beyond testing, Digipath provides cannabis education and training, along with cannabis news coverage, contributing to industry knowledge and best practices. The company's laboratory facility is equipped to perform a wide array of tests, including moisture analysis, water activity assessments, and visual inspections, ensuring a comprehensive approach to quality control. By focusing on testing and education, Digipath aims to support the growth of a safe and regulated cannabis industry in Nevada.

DIGP的投资论点是什么？

Digipath, Inc. presents a focused investment opportunity within the niche market of cannabis and hemp testing. The company's revenue is tied to the growth and regulatory requirements of the Nevada cannabis industry. As the industry matures and regulations become more stringent, the demand for reliable testing services is expected to increase. Digipath's established presence in Las Vegas positions it to capitalize on this trend. However, the company's financial performance, indicated by a negative P/E ratio of -1.91 and a small market capitalization, suggests a high-risk investment profile. Growth catalysts include potential expansion into other states and increased service offerings. The primary risk lies in the competitive landscape and the potential for regulatory changes that could impact the demand for testing services.

DIGP在哪个行业运营？

Digipath, Inc. operates within the rapidly evolving cannabis industry, specifically in the niche of testing and quality assurance. The cannabis market is experiencing substantial growth, driven by increasing legalization and acceptance of cannabis for medical and recreational use. This growth necessitates robust testing services to ensure product safety and compliance with regulations. The competitive landscape includes other testing laboratories and analytical service providers. Digipath's success depends on its ability to maintain high standards of accuracy, reliability, and customer service in a dynamic regulatory environment.

Medical - Diagnostics & Research

Healthcare

DIGP有哪些增长机遇？

Expansion into New Geographic Markets: Digipath could expand its testing services to other states with legalized cannabis markets, such as California, Colorado, and Illinois. The US cannabis testing market is projected to reach $2 billion by 2028. Entering new markets would require establishing new laboratory facilities and obtaining necessary licenses, but it could significantly increase Digipath's revenue and market share. This expansion could begin within the next 2-3 years as more states legalize cannabis.
Development of New Testing Services: Digipath could develop new testing services to address emerging needs in the cannabis industry, such as testing for new contaminants, potency testing for different cannabinoids, and genetic testing of cannabis plants. The market for specialized cannabis testing services is growing rapidly. By offering a wider range of testing options, Digipath could attract new customers and increase revenue from existing clients. This could be implemented within the next 1-2 years.
Partnerships with Cannabis Producers and Dispensaries: Digipath could form strategic partnerships with cannabis producers and dispensaries to provide on-site testing services or to become their preferred testing provider. These partnerships would provide Digipath with a steady stream of testing samples and increase its brand awareness within the cannabis industry. The timeline for establishing these partnerships is within the next year.
Offering Educational and Training Programs: Digipath could expand its educational and training programs for cannabis industry professionals, covering topics such as testing methodologies, quality control, and regulatory compliance. The demand for cannabis education is growing as the industry becomes more regulated. By offering valuable training programs, Digipath could establish itself as a thought leader in the cannabis testing space and generate additional revenue. This initiative could be launched within the next 6-12 months.
Investment in Advanced Testing Technologies: Digipath could invest in advanced testing technologies, such as high-throughput screening and mass spectrometry, to improve the accuracy, speed, and efficiency of its testing services. These technologies would allow Digipath to process a larger volume of samples and provide more detailed testing results. The investment in advanced technologies would enhance Digipath's competitive advantage and attract customers seeking the highest quality testing services. This could be implemented over the next 2-3 years.

Digipath, Inc. operates in the cannabis and hemp testing market, providing essential services to ensure product safety and regulatory compliance.
The company's headquarters are located in Las Vegas, Nevada, positioning it within a key market for the cannabis industry.
Digipath employs 17 individuals, reflecting its scale of operations within the specialized testing sector.
The company's negative P/E ratio of -1.91 indicates that it is not currently profitable, suggesting potential challenges in achieving sustained profitability.
Digipath's beta of 0.42 suggests that its stock price is less volatile than the overall market.

DIGP提供哪些产品和服务？

Provides cannabis and hemp lab testing services.
Screens cannabis for contaminants like pesticides and heavy metals.
Offers testing for residual solvents and microbial contaminants.
Conducts moisture and water activity analysis.
Provides cannabis education and training.
Offers cannabis news coverage.

DIGP如何赚钱？

Generates revenue by charging fees for cannabis and hemp testing services.
Offers testing services to growers, dispensaries, and producers.
Provides education and training programs for cannabis industry professionals.

Licensed medical marijuana enterprises in Nevada.
Cannabis growers.
Cannabis dispensaries.
Cannabis producers.
Caregivers, patients, and end-users of cannabis products.

Specialized expertise in cannabis and hemp testing.
Established presence in the Nevada cannabis market.
Comprehensive testing services covering a wide range of contaminants.
Focus on regulatory compliance and product safety.

什么因素可能推动DIGP股价上涨？

Ongoing: Increasing legalization of cannabis in other states, potentially expanding Digipath's market reach.
Ongoing: Growing demand for cannabis testing services due to stricter regulatory requirements.
Upcoming: Potential partnerships with cannabis producers and dispensaries to secure testing contracts.
Upcoming: Development of new testing services to address emerging needs in the cannabis industry.

DIGP的主要风险是什么？

Potential: Competition from other testing laboratories in the cannabis market.
Potential: Regulatory changes impacting the cannabis industry and testing requirements.
Potential: Fluctuations in the demand for cannabis products affecting testing volumes.
Ongoing: Limited financial disclosure due to OTC Other tier status.
Ongoing: Lower liquidity and wider bid-ask spreads in the OTC market.

DIGP的核心优势是什么？

Specialized cannabis and hemp testing services.
Located in the Nevada cannabis market.
Comprehensive contaminant screening.
Focus on regulatory compliance.

DIGP的劣势是什么？

Small market capitalization.
Negative P/E ratio indicating lack of profitability.
Limited geographic reach.
Dependence on the Nevada cannabis market.

DIGP有哪些机遇？

Expansion into new geographic markets.
Development of new testing services.
Partnerships with cannabis producers and dispensaries.
Offering educational and training programs.

DIGP面临哪些威胁？

Competition from other testing laboratories.
Regulatory changes impacting the cannabis industry.
Fluctuations in the demand for cannabis products.
Potential for new contaminants and testing requirements.

DIGP的竞争对手是谁？

Eurofins Scientific SE — Global testing services provider with a broad range of analytical solutions. — (ETRGF)
Genius Group Ltd — Education company that may offer cannabis-related training programs. — (GNOW)
Novec Holdings Corp — Unknown differentiation based on available data. — (NOVC)
Nutranext Inc — Nutraceutical company that may have testing needs for its products. — (NUTTQ)
Invivo Therapeutics Holdings Corp — Biopharmaceutical company, potentially requiring similar testing standards. — (NVIVQ)

Key Metrics

MoonshotScore: 44/100

Company Profile

CEO: A. Stone Douglass
Headquarters: Las Vegas, US
Employees: 17
Founded: 2012

AI Insight

AI analysis pending for DIGP

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Digipath, Inc. do?

Digipath, Inc. provides comprehensive cannabis and hemp lab testing services to licensed medical marijuana enterprises in Nevada. The company operates a testing laboratory facility that screens cannabis, hemp, and related products for potentially harmful contaminants, including pesticides, heavy metals, and microbial contaminants. Digipath also offers cannabis education and training, along with cannabis news coverage, contributing to industry knowledge and best practices. By ensuring product safety and regulatory compliance, Digipath supports the growth of a safe and regulated cannabis industry in Nevada.

What do analysts say about DIGP stock?

As of March 17, 2026, there is no available analyst coverage or consensus on Digipath, Inc. due to its OTC listing and small market capitalization. Key valuation metrics such as price targets and earnings estimates are not available. Investors should conduct their own independent research and consider the risks associated with investing in OTC stocks, including limited financial disclosure and lower liquidity. Growth considerations include potential expansion into new markets and the development of new testing services.

What are the main risks for DIGP?

The main risks for Digipath, Inc. include competition from other testing laboratories in the cannabis market, regulatory changes impacting the cannabis industry and testing requirements, and fluctuations in the demand for cannabis products. Additionally, as an OTC-listed company, Digipath faces risks associated with limited financial disclosure, lower liquidity, and potential price volatility. The company's dependence on the Nevada cannabis market also poses a risk, as changes in state regulations or market conditions could significantly impact its revenue and profitability.